Patents Assigned to Egen, Inc.
  • Publication number: 20140186375
    Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 3, 2014
    Applicant: EGEN, Inc.
    Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
  • Publication number: 20140050775
    Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 20, 2014
    Applicant: Egen, Inc.
    Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
  • Patent number: 8623837
    Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: January 7, 2014
    Assignee: Egen, Inc.
    Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
  • Publication number: 20140005254
    Abstract: The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 2, 2014
    Applicant: EGEN, INC.
    Inventor: EGEN, INC.
  • Patent number: 8569065
    Abstract: The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: October 29, 2013
    Assignee: EGEN, Inc.
    Inventors: Kevin Polach, Jason Fewell, Khursheed Anwer
  • Publication number: 20130251809
    Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.
    Type: Application
    Filed: March 8, 2013
    Publication date: September 26, 2013
    Applicant: Egen, Inc.
    Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
  • Patent number: 8460696
    Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 11, 2013
    Assignee: Egen, Inc.
    Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
  • Patent number: 8445017
    Abstract: A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents, endosomolytic agents, nuclear localization sequences, pH sensitive endosomolytic peptides, chromogenic or fluorescent dyes.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: May 21, 2013
    Assignee: Egen, Inc.
    Inventors: Gregory Slobodkin, Majed Matar, Jason Fewell, Khursheed Anwer
  • Publication number: 20130065942
    Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 14, 2013
    Applicant: Egen, Inc.
    Inventors: Majed Matar, Jason Fewell, Danny H. Lewis, Khursheed Anwer
  • Patent number: 8057821
    Abstract: A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents, endosomolytic agents, nuclear localization sequences, pH sensitive endosomolytic peptides, chromogenic or fluorescent dyes.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: November 15, 2011
    Assignee: EGEN, Inc.
    Inventors: Gregory Slobodkin, Majed Matar, Jason Fewell, Khursheed Anwer
  • Patent number: 7964571
    Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: June 21, 2011
    Assignee: Egen, Inc.
    Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
  • Publication number: 20100233141
    Abstract: The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.
    Type: Application
    Filed: March 15, 2010
    Publication date: September 16, 2010
    Applicant: EGEN, INC.
    Inventors: Kevin Polach, Jason Fewell, Khursheed Anwer